Microbion Biosciences is a Bozeman, Montana, USA, biotechnology that is developing a new class of antibiotics....
Fantastic news! We've Found the answer you've been seeking!
Question:
Transcribed Image Text:
Microbion Biosciences is a Bozeman, Montana, USA, biotechnology that is developing a new class of antibiotics. The primary market that Microbion intends to develop is the diabetic foot ulcer (DFU) market for North America. The International Diabetes Federation Atlas indicates that in 2015 there were 44 million people in North America with diabetes, and this population is expected to grow to 61 million in 2040. Microbion's studies indicate that about 10% of people with diabetes in North America develop chronic foot ulcers and would benefit from their product. Microbion believes that it will successfully have a DFU product on the market by Jan 1, 2019. The total market unit sales in 2019 is forecast to be 440,000 units, and Microbion believes that it can get 20% of that total market. Microbion forecasts that total market size will increase by 1.5% each year through at least 2040. Unfortunately, Microbion's patent protection expires on December 31, 2026, so Microbion expects to have only 7 years of patent protection for its product. Upon the expiration of the patent, generics are expected to enter the market and decrease the market price of the product such that cash flows after the patent expiration will have zero net present value. The expected product price for the Microbion DFU product is $1200, and that price is expected to hold through Microbion's patent protection period which ends at the end of 2026 (although inflation would be expected to push prices up, the market power of federal government is expected to keep prices constant). Prices will adjust downward in 2027 when generics enter the market. The total costs of goods sold of producing the product are 20% of sales, and the sales, general and administrative expenses are expected to be 30% of sales. In order to continue with this project, Microbion will need to invest $21,000,000 on January 1, 2017 for the Phases 3 study which is expected to be completed in September 2017. This investment will be depreciated on a straight line basis for 7 years (through 2025), but the first year of depreciation will not occur until 2019, which is the first year of positive revenue. In addition, Microbion will need to increase the Net Working Capital of the company in 2019 by $2,000,000. These funds WILL NOT be returned at the end of the project. The probability that Microbion will successfully complete the Phase 3 study and have its DFU product accepted for the market is 75%. You have done sufficient due diligence on the numbers that Microbion has provided and have confirmed from your own sources that they are appropriate. You have determined that the appropriate cost of capital for this project is 18%. The corporate tax rate for Microbion is 35%. You also know that a multiplier of 1.2 times last year's sales is a multiplier used for valuation in the antibiotic industry. Based on the information that you have already collected and any assumptions that you need to make, determine a valuation for Microbion as if it is January 1, 2017. Clearly explain and justify how you arrived at this valuation. Discuss the different valuation approaches that are available to you, and explain why you used the approach(es) that you used. Microbion Biosciences is a Bozeman, Montana, USA, biotechnology that is developing a new class of antibiotics. The primary market that Microbion intends to develop is the diabetic foot ulcer (DFU) market for North America. The International Diabetes Federation Atlas indicates that in 2015 there were 44 million people in North America with diabetes, and this population is expected to grow to 61 million in 2040. Microbion's studies indicate that about 10% of people with diabetes in North America develop chronic foot ulcers and would benefit from their product. Microbion believes that it will successfully have a DFU product on the market by Jan 1, 2019. The total market unit sales in 2019 is forecast to be 440,000 units, and Microbion believes that it can get 20% of that total market. Microbion forecasts that total market size will increase by 1.5% each year through at least 2040. Unfortunately, Microbion's patent protection expires on December 31, 2026, so Microbion expects to have only 7 years of patent protection for its product. Upon the expiration of the patent, generics are expected to enter the market and decrease the market price of the product such that cash flows after the patent expiration will have zero net present value. The expected product price for the Microbion DFU product is $1200, and that price is expected to hold through Microbion's patent protection period which ends at the end of 2026 (although inflation would be expected to push prices up, the market power of federal government is expected to keep prices constant). Prices will adjust downward in 2027 when generics enter the market. The total costs of goods sold of producing the product are 20% of sales, and the sales, general and administrative expenses are expected to be 30% of sales. In order to continue with this project, Microbion will need to invest $21,000,000 on January 1, 2017 for the Phases 3 study which is expected to be completed in September 2017. This investment will be depreciated on a straight line basis for 7 years (through 2025), but the first year of depreciation will not occur until 2019, which is the first year of positive revenue. In addition, Microbion will need to increase the Net Working Capital of the company in 2019 by $2,000,000. These funds WILL NOT be returned at the end of the project. The probability that Microbion will successfully complete the Phase 3 study and have its DFU product accepted for the market is 75%. You have done sufficient due diligence on the numbers that Microbion has provided and have confirmed from your own sources that they are appropriate. You have determined that the appropriate cost of capital for this project is 18%. The corporate tax rate for Microbion is 35%. You also know that a multiplier of 1.2 times last year's sales is a multiplier used for valuation in the antibiotic industry. Based on the information that you have already collected and any assumptions that you need to make, determine a valuation for Microbion as if it is January 1, 2017. Clearly explain and justify how you arrived at this valuation. Discuss the different valuation approaches that are available to you, and explain why you used the approach(es) that you used.
Expert Answer:
Answer rating: 100% (QA)
To determine the valuation for Microbion as of January 1 2017 we can use a combination of valuation approaches including the discounted cash flow DCF ... View the full answer
Related Book For
Posted Date:
Students also viewed these accounting questions
-
Managing Scope Changes Case Study Scope changes on a project can occur regardless of how well the project is planned or executed. Scope changes can be the result of something that was omitted during...
-
Read the case study "Southwest Airlines," found in Part 2 of your textbook. Review the "Guide to Case Analysis" found on pp. CA1 - CA11 of your textbook. (This guide follows the last case in the...
-
Planning is one of the most important management functions in any business. A front office managers first step in planning should involve determine the departments goals. Planning also includes...
-
On 1 June 1998, Alice bought a house in Derby for 45,000. - She occupied the house as her PPR until 1 May 2000 when she left to work in Exeter, living in rented accommodation. - She returned to the...
-
From among the molecules and ions shown, all of which are based on cycloundecapentaene, identify those which satisfy the criteria for aromaticity as prescribed by Hackles rule.
-
Iris tried not to smile. Of course, it isnt technically a disaster, she explained, but I understand what you mean. How much information is lost? Joel looked at her in dismay. Lost? All of it! We had...
-
Quarterly reporting is essential in the interest of transparency and can, therefore, only be beneficial for investors. Discuss.
-
Given 150 units of beginning inventory, a lead time of one period, an ordering cost of $400 per order, and a holding cost of $2 per unit per period, determine which lot sizing technique would result...
-
Solve for 0 if -8sin0-4=-43--4 and 00 <2. List your answers as exact answers in terms of , separated by a comma if necessary.
-
In Part III (Appendix 11B) of the audit case, the audit staff of Adams, Barnes & Co. identified specific revenue risks on working paper RA-12 (page 494). However, the Summary of Audit Approach...
-
1: A company offers 9 percent rate of interest on deposits. What is the effective rate of interest if the compounding is done? i) Half yearly ii) Quarterly iii) Monthly 2: Mr. X has to receive...
-
Oil is siphoned from the bottom of an atmospheric ( open ) feeding tank to a lower level tank through a 2 c m diameter pipe 4 0 m in length. The bottom of the feeding tank is 1 . 5 m above the exit...
-
Can you elaborate on the mechanisms of localized corrosion, such as pitting and crevice corrosion, and discuss the microstructural and environmental conditions that contribute to their initiation and...
-
Answer the questions using the following graph. D 20 B 27 5 F 8 14 A E 17 12 30 10 G 15 7 G (a) Draw the sequence of edges (represented by edge weight) added to the minimal-cost spanning tree...
-
Which has a greater impact on effective patient care ethics or law? justify your answer.
-
Explain the joint venture and partnerships that occur between Chinese Private Equity Firms,Western private equity firms , western firms and Chinese firms
-
Saved Help Problem 2-17 Balance Sheet (LG2-1) Mikey's Bar and Grill has total assets of $11 million, of which $4 million are current assets. Cash makes up 10 percent of the current assets and...
-
(a) Given a mean free path = 0.4 nm and a mean speed vav = 1.17 105 m/s for the current flow in copper at a temperature of 300 K, calculate the classical value for the resistivity of copper. (b)...
-
On March 1, Midway Distribution Company is considering leasing a building and buying the necessary equipment to operate a public warehouse. Alternatively, the company could use the funds to invest in...
-
Using the data in Exercise 6-10, assume that during the second year of operations Master Plumbing Supply Co. had net sales of $4,200,000, wrote off $60,000 of accounts as uncollectible using the...
-
Financial information related to Joshua Tree Interiors for August and September 2010 is as follows: a. Prepare balance sheets for Joshua Tree Interiors as of August 31 and as of September 30, 2010.b....
-
Prepare the operating budget, the financial budget, and the supporting schedules.
-
Distinguish between operating and financial budgets.
-
Follow the principal steps in preparing a master budget.
Study smarter with the SolutionInn App